U.S. FDA has granted Priority Review for OLYSIO® in combination with sofosbuvir supplementary New Drug Application

        Print
| Source: Medivir AB
Stockholm, Sweden — Medivir AB (OMX: MVIR) announces that the Food and Drug
Administration (FDA) has assigned a Priority Review designation to the
supplemental New Drug Application (sNDA) for the use of once-daily Olysio
(simeprevir) in combination with sofosbuvir for 12 weeks treatment of adult
patients with genotype 1 chronic hepatitis C. The sNDA was filed in May by
Medivir’s strategic partner Janssen Research & Development LLC.

The regulatory submission for Olysio and sofosbuvir is supported by data from
the phase II COSMOS study which included treatment-naïve patients with advanced
fibrosis (METAVIR F3 to F4 scores) and prior null-responder patients with all
stages of liver fibrosis (METAVIR F0 to F4 scores).

“The Priority Review designation by the FDA shows the high priority and great
importance of making interferon-free treatment regiments available to the many
difficult to cure hepatitis C patients groups“, says Charlotte Edenius, EVP
Development, Medivir.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292

About Olysio®
Olysio is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland
and Medivir AB and indicated for the treatment chronic hepatitis C infection in
combination with pegylated interferon and ribavirin in HCV genotype 1 and 4
infected patients with compensated liver disease, including cirrhosis.

Janssen is responsible for the global clinical development of Olysio and has
exclusive, worldwide marketing rights, except in the Nordic countries. Medivir
AB retains marketing rights for Olysio in these countries under the marketing
authorization held by Janssen-Cilag International NV. Olysio was approved for
the treatment of chronic hepatitis C infection as part of an antiviral treatment
regimen in combination with pegylated interferon and ribavirin in genotype 1
infected adults with compensated liver disease, including cirrhosis in September
2013 in Japan, in November 2013 in Canada and the U.S. and in March 2014 in
Russia. Following the EMA approval, it is anticipated that Olysio will be
available across a number of European Union countries in conjunction with
reimbursement, in the second half of 2014.

About Medivir
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is Olysio, a
novel protease inhibitor for the treatment of hepatitis C that is being
developed in collaboration with Janssen R&D Ireland. The company is also working
with research and development in other areas, such as bone disorders and
neuropathic pain. Medivir has also a broad product portfolio with prescription
pharmaceuticals in the Nordics.